Clinical Immunology Communications最新文献_第7页

Reduced immune system responsiveness in fibromyalgia - A pilot study 纤维肌痛患者免疫系统反应性降低-一项初步研究

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.02.003

Sophia Björkander , Malin Ernberg , Indre Bileviciute-Ljungar

{"title":"Reduced immune system responsiveness in fibromyalgia - A pilot study","authors":"Sophia Björkander , Malin Ernberg , Indre Bileviciute-Ljungar","doi":"10.1016/j.clicom.2022.02.003","DOIUrl":"10.1016/j.clicom.2022.02.003","url":null,"abstract":"<div><p>Fibromyalgia is characterized by widespread musculoskeletal and joint pain, stiffness, fatigue, and sleep and mood disorders. However, the involvement of the immune system in the pathways of fibromyalgia is unclear. The aim of this study was to explore the role of the immune system in comparison with healthy controls and in association with clinical symptoms. Thirteen women with fibromyalgia and 14 controls were included. Peripheral blood mononuclear cells were stimulated and analysed by flow cytometry, and interferon gamma (IFN-γ) and interleukins were measured. Among clinical symptoms, the fibromyalgia group showed decreased cold pain threshold. Immunologically, they had a higher percentage of monocytes, a lower percentage of CD19<sup>+</sup> B<em>-</em>cells, and lower secretion of IFN-γ after stimulation. Decreased capacity to secrete IFN-γ was significantly correlated with decreased cold pain threshold in the fibromyalgia group. These results confirm the presence of immune aberrations in fibromyalgia, at least partially responsible for the associated pain.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"2 ","pages":"Pages 46-53"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000063/pdfft?md5=f52a4a08e3ba783db8bbe070c073ee4f&pid=1-s2.0-S2772613422000063-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74085625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Inhibiting VEGF in cancer immunotherapy 抑制肿瘤免疫治疗中的VEGF

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2021.12.003

Masahiko Shibata , Koji Kono , Seiichi Takenoshita

引用次数: 2

A case of de novo seronegative inflammatory oligoarthritis associated with COVID-19 infection 新发血清阴性炎性少关节炎合并COVID-19感染1例

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.10.001

Lily H. Sung MD , Natalya Surmachevska DO , Jose E. Rubio MD

引用次数: 1

SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria 奥地利接种疫苗和康复队列的SARS-CoV-2抗体测定

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.08.001

Elisabeth Mara, Tobias Mader, Johannes Gratzer, Stefanie Hochegger, Thomas Pekar

引用次数: 1

Myocarditis following Coronavirus vaccination 冠状病毒疫苗接种后心肌炎

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.11.001

Khouloud Ferchichi , Imen Aouinti , Ahmed Zaiem , Ghozlane Lakhoua , Widd Kaabi , Ons Charfi , Sarrah Kastalli , Riadh Daghfous , Sihem El Aidli

{"title":"Myocarditis following Coronavirus vaccination","authors":"Khouloud Ferchichi , Imen Aouinti , Ahmed Zaiem , Ghozlane Lakhoua , Widd Kaabi , Ons Charfi , Sarrah Kastalli , Riadh Daghfous , Sihem El Aidli","doi":"10.1016/j.clicom.2022.11.001","DOIUrl":"10.1016/j.clicom.2022.11.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Myocarditis is an adverse reaction discovered after the marketing of SARS-CoV-2 mRNA vaccines. Nevertheless, this effect is not mentioned as an adverse reaction in the summary of product characteristics of other types of vaccines against this disease.</p></div><div><h3>Objective</h3><p>In this work, we aim to present the cases of myocarditis after vaccination against COVID-19 reported to the national Tunisian centre of pharmacovigilance.</p></div><div><h3>Method</h3><p>We present the cases of myocarditis reported after the COVID-19 vaccination. All cases are diagnosed according to Brighton's case definition of myocarditis. The vaccines causality assessment was estimated by the French imputability updated method of Bégaud et al.</p></div><div><h3>Results</h3><p>We included five patients. The sex ratio (M/F) was 4. The mean age was 30 years. All patients had no notable cardiovascular history and did not report any significant past medical history. The onset of symptoms was two days post-vaccination in three patients. The predominant reported symptoms are chest pain and dyspnea in the five cases. Cardiac magnetic resonance imaging (MRI) confirmed the myocarditis diagnosis in four patients (not performed for one patient).</p><p>All cases were classified as definitive cases according to the Brighton case definition of myocarditis. No patient required hospitalization in a cardiac intensive care unit. All the patients recovered from acute myocarditis within a few days.</p></div><div><h3>Conclusion</h3><p>Reported cases of myocarditis post-COVID-19 vaccination in our population are rare, not severe, and have a quick favorable outcome.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"2 ","pages":"Pages 162-164"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000270/pdfft?md5=69501bc1319cb7b5556cfb9f79c46041&pid=1-s2.0-S2772613422000270-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84157430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Potential role of uric acid to activate NLRP3 inflammasome triggering endothelial dysfunction in preeclampsia 尿酸激活NLRP3炎性体引发子痫前期内皮功能障碍的潜在作用

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.03.003

Priscila Rezeck Nunes , Mariana Romao-Veiga , Maria Terezinha Serrao Peracoli , Jose Carlos Peracoli , Valeria Cristina Sandrim

{"title":"Potential role of uric acid to activate NLRP3 inflammasome triggering endothelial dysfunction in preeclampsia","authors":"Priscila Rezeck Nunes , Mariana Romao-Veiga , Maria Terezinha Serrao Peracoli , Jose Carlos Peracoli , Valeria Cristina Sandrim","doi":"10.1016/j.clicom.2022.03.003","DOIUrl":"10.1016/j.clicom.2022.03.003","url":null,"abstract":"<div><p>Preeclampsia (PE) is a pregnancy-related disorder associated with increasing maternal death rates and affecting 2–8% of pregnant women worldwide. Arterial hypertension and proteinuria, followed by other maternal dysfunctions are classic clinical parameters to identify this disease. Furthermore, hyperuricemia is strictly related to PE, and high plasmatic levels of uric acid have been associated with disease severity. The inflammation in the endothelium caused by danger signals, such as uric acid crystals, is persistent and stimulates the release of inflammatory cytokines, and activates the NLRP3 inflammasome. The mechanisms underlying endothelial dysfunction induced by the metabolism of uric acid, and consequently increased levels of inflammation and oxidative stress in women with PE could be ameliorated with interventions related to inhibition of the NLRP3 activation MSU-mediated and may improve the prognostics of this disease.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"2 ","pages":"Pages 69-75"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000099/pdfft?md5=2abae82803dace4956bc669db3ddfbd1&pid=1-s2.0-S2772613422000099-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90294927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

High neutrophil/lymphocyte ratio and low lymphocyte percentage are independent risk factors for new-onset CKD 中性粒细胞/淋巴细胞比值高和淋巴细胞百分比低是新发CKD的独立危险因素

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.11.003

Mengyuan Guo , Zhaohui Wang , Rui Yang , Kun Liu , Junchao Zeng , Tianhui An

{"title":"High neutrophil/lymphocyte ratio and low lymphocyte percentage are independent risk factors for new-onset CKD","authors":"Mengyuan Guo , Zhaohui Wang , Rui Yang , Kun Liu , Junchao Zeng , Tianhui An","doi":"10.1016/j.clicom.2022.11.003","DOIUrl":"10.1016/j.clicom.2022.11.003","url":null,"abstract":"<div><p>Chronic kidney disease (CKD) is one of the major public health problems worldwide, and inflammation is a noticeable cause of CKD. A total of 5508 non-CKD patients were enrolled in our prospective study and followed for three years, with 1.25% (<em>n</em> = 69) participants having newonset CKD at the endpoint. After adjustment for potential confounders, we found that High NLR and low LYMPH% are two independent risk factors for new-onset CKD: Compared with the lowest NLR tertile, the multifactor corrected OR (95% CI) of the highest tertile was 2.47(1.20–5.09), <em>P</em> = 0.014; And adjusted OR (95% CI) was 0.31(0.16–0.62) for the highest LYMPH% tertile, <em>P</em> = 0.001. The model constructed with NLR, LYMPH%, and other risk factors had favourable predictive power for new-onset CKD with an AUC of 0.82 (95% CI, 0.76–0.88). Assessment of NLR and LYMPH% may be helpful for early warning of CKD occurrence.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"2 ","pages":"Pages 165-171"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000294/pdfft?md5=f75317f6ec969ade80737d050d6208a6&pid=1-s2.0-S2772613422000294-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83313350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meningoradiculitis post-COVID-19 mRNA vaccination: A case report covid -19 mRNA疫苗接种后脑膜根炎1例报告

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.03.004

Alexandre Landry , Stéphanie Crapoulet , Luc H. Boudreau , Christine Bourque , Lyle Weston , Nicholas Pilote , Guillaume Desnoyers , Ludivine Chamard-Witkowski

{"title":"Meningoradiculitis post-COVID-19 mRNA vaccination: A case report","authors":"Alexandre Landry , Stéphanie Crapoulet , Luc H. Boudreau , Christine Bourque , Lyle Weston , Nicholas Pilote , Guillaume Desnoyers , Ludivine Chamard-Witkowski","doi":"10.1016/j.clicom.2022.03.004","DOIUrl":"10.1016/j.clicom.2022.03.004","url":null,"abstract":"<div><p>We present a rare case of meningoradiculitis occurring after mRNA COVID-19 vaccination.</p><p>This patient, with a history of inflammatory arthritis following rubella vaccination, presented to the emergency department 4 days after her vaccination with both central and radicular nervous system symptoms. Symptoms included pain, sensory and motor deficits in L5 roots distribution, along with signs of central irritation, such as headache, difficulty concentrating and a Babinski sign. MRI showed bilateral L5 nerve roots enhancement. Lumbar puncture showed elevated protein and IgG, and relevant serologies excluded common causes. Prednisone and physical therapy helped the patient to achieve near complete recovery nine weeks after presentation.</p><p>We concluded that this patient presented meningoradiculitis probably secondary to her vaccination in a context of possible overactive immune system. While such presentations might be rare, and do not constitute a general reason to abstain from vaccination, they must be well recognized and treated.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"2 ","pages":"Pages 76-78"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000105/pdfft?md5=3a42b22b1b8337eb4f2e493f37c1fab0&pid=1-s2.0-S2772613422000105-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89045166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Covid-19 Vaccine safety and adverse event analysis from Pakistan 巴基斯坦Covid-19疫苗安全性和不良事件分析

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.05.003

Syed Shahzad Hasan , Abdur Rashid , Sundus Osama , Zia Ul Mustafa , Hamid A. Merchant

{"title":"Covid-19 Vaccine safety and adverse event analysis from Pakistan","authors":"Syed Shahzad Hasan , Abdur Rashid , Sundus Osama , Zia Ul Mustafa , Hamid A. Merchant","doi":"10.1016/j.clicom.2022.05.003","DOIUrl":"10.1016/j.clicom.2022.05.003","url":null,"abstract":"<div><p>Covid immunization commenced on 2nd Feb 2021 in Pakistan and as of 7th Sep 2021, over 84 million vaccine doses were administered in Pakistan, of which 72% procured by the government, 22% received through Covax and 6% were donated. The vaccines rolled out nationally included: Sinopharm, Sinovac and CanSinoBIO (China), AstraZeneca (UK), Moderna and Pfizer (USA), Sputnik (Russia), and PakVac (China/Pakistan). About half of the eligible population in Pakistan (63 m) had received at least one dose of Covid vaccine as of Sep 2021. Pakistan National Pharmacovigilance Centre (PNPC) in coordination with WHO, MHRA and Uppsala Monitoring Centre (UMC) established pharmacovigilance centers across Pakistan. The Covid vaccine AEFIs in Pakistan were mainly reported via NIMS (National Immunization Management System), COVIM (Covid-19 Vaccine Inventory Management System), 1166 freephone helpline and MedSafety. There have been 39,291 ADRs reported as of 30th Sept 2021, where most reported after the first dose (<em>n</em> = 27,108) and within 24–72 h of immunization (<em>n</em> = 27,591). Fever or shivering accounted for most AEFI (35%) followed by injection-site pain or redness (28%), headache (26%), nausea/vomiting (4%), and diarrhoea (3%). 24 serious AEFIs were also reported and investigated in detail by the National AEFI review committee. The rate of AEFIs reports ranged from 0.27 to 0.79 per 1000 for various Covid vaccines in Pakistan that was significantly lower than the rates in UK (∼4 per 1000), primarily atrributed to underreporting of cases in Pakistan. Finally, Covid vaccines were well tolerated and no significant cause for concern was flagged up in Pakistan's Covid vaccine surveillance system concluding overall benefits outweighed risks.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"2 ","pages":"Pages 91-97"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000154/pdfft?md5=c5f792b4c679597f1d020f0a7e3929ef&pid=1-s2.0-S2772613422000154-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74011765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood Nasalferon是一种新的IFNα2b鼻用制剂，可调节粘膜和血液中与抗病毒反应相关的细胞和分子因子

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.02.002

Dania Vázquez-Blomquist , Mónica Bequet-Romero , Yssel Mendoza-Marí , Gilda Lemos , Iris Valdés , Camila Canaán-Haden Ayala , Isabel Gonzáles Moya , Ricardo Martínez Rosales , Giselle Freyre Corrales , Gerardo Guillén-Nieto

引用次数: 1